This dual role makes DPPIV a potential therapeutic target not just for limiting viral entry, but for managing the chronic complications, such as stroke and cognitive decline, that are linked to metabolic and cerebrovascular dysregulation in COVID-19 survivors. The gene discussed is DPP4; the disease is COVID-19.